CVS Health Corporation has announced robust fourth quarter and full-year results, with shares surging more than 14% after beating earnings expectations. Despite wrestling with high medical costs, particularly affecting its insurance segment Aetna, CVS reported a Q4 profit of $1.6 billion and a revenue increase of 4.2% to $97.7 billion. The company experienced a notable rise in same-store prescription volume of 5.9%, contributing to an optimistic outlook for fiscal year 2025. Although CVS continues to face challenges in the retail pharmacy sector and high medical expenses, it aims for a turnaround under its new CEO. The latest results have positioned CVS as a leading performer in the S&P 500, reflecting investor confidence in its recovery strategy.